Brind.

Viatris and Theravance are collaborating on product sales involving Yupelri, with Viatris recording product sales on August 14, 2025.

1 report, 1 independent Updated Aug 14

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Theravance Biopharma (United States)Mylan

Keep exploring

The entities involved

Theravance Biopharma (United States)
company in San Francisco, United States

Nothing else this week.
Mylan
former pharmaceutical company
- Mylan and Zymeworks are involved in a deal aimed at bolstering Zymeworks’ commercial portfolio, related to COPD therapy.Mon 11:01
- Zymeworks is leveraging Irish tax attributes as part of its deal with Mylan.Mon 11:01

Coverage

Newest first; wire copies grouped

Aug 14ZacksTheravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y Theravance Biopharma TBPH reported second-quarter 2025 adjusted net loss of 8 cents per share, which was narrower than the Zacks Consens